iiinova — where your digital self keeps evolving

Not planning to head to ESMO? TOGA's got you covered. Join us as we present the latest thoracic cancer highlights from the 2026 ESMO Congress. Registrations Now Open: buff.ly/L8MM2RZ

100

TOGA @togaanz.bsky.social · 30/09/2026

VEGF: Targeted therapies continue to show promise In our latest episode of Conversations in Lung Cancer Research, A/Prof Prunella Blinman, Prof Nick Pavlakis and Prof Sanjay Popat discuss the growing evidence and emerging approaches in VEGF-targeted treatment. 🎧 Listen to the full episode now.

100

TOGA @togaanz.bsky.social · 29/09/2026

In this episode of Conversations in Lung Cancer Research, A/Prof Prunella Blinman, Prof Nick Pavlakis and Prof Sanjay Popat explore emerging treatment strategies and where the field may be heading. This podcast is sponsored by BioNTech. Listen on Apple > buff.ly/7Id1pCO

100

TOGA @togaanz.bsky.social · 28/09/2026

What does a KRAS G12C mutation mean for people with lung cancer? Our latest blog explains: - What KRAS G12C is and how it is identified - How targeted treatments work - What treatment options and access pathways are available in Australia - How clinical trials are helping advance KRAS G12C

buff.ly

What is KRAS G12C Lung Cancer? Understanding Targeted Treatment and Clinical Trials - TOGA - Thoracic Oncology Group Australasia

Learn what a KRAS G12C mutation means, how targeted therapies work, and how Australian clinical trials are testing new lung cancer treatments.

100

TOGA @togaanz.bsky.social · 26/09/2026

On Mesothelioma Awareness Day, we recognise the ongoing impact of mesothelioma on individuals, families and communities, and the importance of sustained research and clinical progress. Awareness remains essential to improving diagnosis, care and access to emerging treatments.

100

TOGA @togaanz.bsky.social · 25/09/2026

The latest episode is out now 🎧 A/Prof Prunella Blinman is joined by world-leading thoracic medical oncologists Prof Nick Pavlakis and Prof Sanjay Popat to discuss VEGF and its evolving role in thoracic malignancies. This podcast is sponsored by BioNTech. Listen on Apple > buff.ly/7Id1pCO

100

TOGA @togaanz.bsky.social · 24/09/2026

What’s next for VEGF-targeted therapies in thoracic cancer? In the latest episode of Conversations in Lung Cancer Research, A/Prof Prunella Blinman is joined by Prof Nick Pavlakis and Prof Sanjay Popat to explore the evolving role of VEGF in thoracic malignancies.

100

TOGA @togaanz.bsky.social · 22/09/2026

WCLC 2026: What matters for thoracic cancer care? The 2026 IASLC World Conference on Lung Cancer delivered important new data across thoracic cancers. But which findings are most likely to influence practice? Join us as our speakers unpack the most significant WCLC 2026 highlights, with a focus

110

TOGA @togaanz.bsky.social · 21/09/2026

A warm welcome and thank you to Arrotex Pharmaceuticals for joining us as a sponsor of TOGA's 2026 Lung Cancer Preceptorship. Through expert-led sessions, case discussions and opportunities to connect with colleagues, the Preceptorship supports the professional development of emerging clinicians

100

TOGA @togaanz.bsky.social · 20/09/2026

🚨 Applications close today! Today is the final opportunity to submit your application for TOGA's Inspirational Research Grant. If you have an early-stage research project with the potential to advance thoracic oncology, make sure your application is submitted before the deadline.

100

TOGA @togaanz.bsky.social · 19/09/2026

🫁 Two major international conferences. One webinar bringing together the key thoracic cancer updates. Join TOGA for our International Conference Highlights webinar, where expert speakers will unpack significant findings from WCLC and ASTRO 2026 and explore their potential impact on local

110

TOGA @togaanz.bsky.social · 17/09/2026

⏰ Last chance to apply! Applications for TOGA's Inspirational Research Grant close soon. If you have an innovative research idea in thoracic oncology, now is the time to submit your application and take the next step towards turning your vision into impact. Grant details: 💰 Amount: $50,000

100

TOGA @togaanz.bsky.social · 16/09/2026

Recognising rare mutations starts at diagnosis. 🎧 Listen to the full episode for more insights into testing, diagnosis and treatment. This podcast is sponsored by Bristol Myers Squibb. Listen on Apple > buff.ly/TP6kW90 Spotify > buff.ly/vL41W9r Show notes > buff.ly/Iet71To

000

TOGA @togaanz.bsky.social · 15/09/2026

If you learn nothing more, learn this... Professor Sanjay Popat reviews the management of atypical EGFR mutations in NSCLC, arguing that the broad label “EGFR-positive” is clinically unhelpful because different EGFR mutations have distinct biology, drug sensitivity and treatment implications.

100

TOGA @togaanz.bsky.social · 14/09/2026

🚨 Applications closing soon! The ALK+ NSCLC Inspirational Research Grant, proudly supported by TOGA and ALK Positive Australia, provides vital funding to support research that can improve understanding, treatment and care for Australians living with ALK+ NSCLC Could your research help shape the

110

TOGA @togaanz.bsky.social · 13/09/2026

We’re pleased to welcome Johnson & Johnson as a sponsor of our International Conference Highlights – WCLC & ASTRO 2026 webinar. With their support, we’re able to bring our community together to hear expert insights into the latest thoracic cancer research and its potential impact on local practice.

100

TOGA @togaanz.bsky.social · 12/09/2026

A warm welcome and thank you to Medison for supporting TOGA's 2026 Lung Cancer Preceptorship. Your partnership helps make high-quality education and collaboration possible for emerging clinicians with an interest in thoracic oncology. We're grateful to have you on board.

001

TOGA @togaanz.bsky.social · 10/09/2026

📢 Last day to submit! If you’re planning to share your research concept for this round, make sure it’s in today. And if you miss the cut-off, don’t panic. The Scientific Committee continually reviews new concepts, so you’ll have more opportunities in 2027. Keep an eye out for

100

TOGA @togaanz.bsky.social · 10/09/2026

The treatment landscape for ROS1-positive NSCLC has expanded significantly. In the latest episode, the panel discusses the growing number of treatment options available and what this means for navigating patient care. Listen on Apple > buff.ly/TP6kW90 Spotify > buff.ly/vL41W9r

100

TOGA @togaanz.bsky.social · 10/09/2026

🚨 Applications closing soon! Have you submitted your application for TOGA's Inspirational Research Grant? We're looking for innovative research ideas that involve consumer voices and have the potential to make a meaningful difference in thoracic oncology. Grant details: 💰 Amount: $50,000

111

TOGA @togaanz.bsky.social · 09/09/2026

🫁 What were the key thoracic cancer takeaways from WCLC 2026? Join us for our webinar exploring the most important research and clinical updates from the 2026 IASLC World Conference on Lung Cancer (WCLC). Our expert speakers will unpack the findings that matter most in thoracic oncology and

100

TOGA @togaanz.bsky.social · 09/09/2026

A/Prof Malinda Itchins provides an update on ADOPT-Lung at the TOGA ASM 2026. This clinical trial is designed to determine if early-stage NSCLC patients who receive chemotherapy and immunotherapy prior to surgery have longer disease-free survival if they are also treated with immunotherapy after

youtu.be

ADOPT-Lung Recruitment Update | A/Prof Malinda Itchins | TOGA ASM 2026

A/Prof Malinda Itchins provides an update on ADOPT-Lung at the TOGA ASM. This clinical trial is designed to determine if early-stage NSCLC patients who receive chemotherapy and immunotherapy prior…

100

TOGA @togaanz.bsky.social · 08/09/2026

What role does CNS activity play in treating ROS1-positive NSCLC? In TOGA’s Conversations in Lung Cancer Research, the panel discusses the evolving intracranial activity of therapies for ROS1-positive lung cancer and what this may mean for treatment decisions. Listen to the full episode for

100

TOGA @togaanz.bsky.social · 08/09/2026

New research is providing valuable insights into surgical approaches for people with early-stage lung cancer. In our latest blog, we explore the findings and what they could mean for lung cancer treatment and patient care. Read the full blog > thoraciconcology.org.au/news/treatme...

thoraciconcology.org.au

Lung Cancer Surgery: Do You Need Your Whole Lung Lobe Removed? - TOGA - Thoracic Oncology Group Australasia

New evidence is changing the way surgeons approach early-stage lung cancer, with lung-sparing surgery becoming an option for carefully selected patients.

001

TOGA @togaanz.bsky.social · 07/09/2026

Today, on World Radiotherapy Awareness Day, we recognise the vital role radiotherapy plays in cancer care. For many people diagnosed with thoracic cancer, radiotherapy is an important part of treatment – helping to treat cancer, manage symptoms and improve quality of life. This year's theme,

100

TOGA @togaanz.bsky.social · 07/09/2026

What does My Brilliant Career and being a Lung Cancer Nurse have in common? Mary Duffy AM gives a presentation on the need for lung cancer survivorship clinics and how she was able to develop a comprehensive patient-centred survivorship care through a precinct-wide nurse-led survivorship clinic.

100

TOGA @togaanz.bsky.social · 06/09/2026

Don't miss your opportunity to bring your research vision to life. Applications for TOGA's Inspirational Research Grant is now open, providing support to promising early-stage research in thoracic oncology. Grant details: 💰 Amount: $50,000 📆 Duration: Two years

100

TOGA @togaanz.bsky.social · 05/09/2026

A sincere thank you to Johnson & Johnson for supporting TOGA's 2026 Lung Cancer Preceptorship. Your contribution helps bring together emerging clinicians and experienced faculty to share knowledge, explore the latest evidence and strengthen the future of thoracic oncology.

000

TOGA @togaanz.bsky.social · 04/09/2026

🎧 Out now: A new episode of TOGA's Conversations in Lung Cancer Research. Host A/Prof Steven Kao is joined by A/Prof Venessa Chin and Dr Ben Kong to explore the clinical features of ROS1-positive non-small cell lung cancer and the evolving diagnostic and treatment landscape in Australia.

100

TOGA @togaanz.bsky.social · 03/09/2026

🎙️ New episode dropping tomorrow In the next episode of TOGA's Conversations in Lung Cancer Research, we take a closer look at ROS1-positive non-small cell lung cancer. Available tomorrow wherever you get your podcasts. This podcast is sponsored by Bristol Myers Squibb.

000

TOGA @togaanz.bsky.social · 03/09/2026

📣 Registrations are now open! Join us for Thoracic Cancer Highlights from WCLC 2026, where our expert speakers will unpack the most significant findings from the 2026 IASLC WCLC. Hear what the latest research could mean for thoracic cancer care and how these developments may impact local clinical

100

TOGA @togaanz.bsky.social · 03/09/2026

⏰ Last chance to express your interest! Expressions of interest for TOGA’s 2026 Lung Cancer Preceptorship close tomorrow. If you’re an early-career clinician with an interest in thoracic oncology, don’t miss the opportunity to take part in two days of expert-led education, interactive case

100

TOGA @togaanz.bsky.social · 02/09/2026

Step outside your comfort zone. Prof Zarnie Lwin OAM shares why leaving your home institution and experiencing a different environment can be such an important part of professional growth. In this episode of TOGA's Conversations in Lung Cancer Research, she reflects on the impact of her

100

TOGA @togaanz.bsky.social · 31/08/2026

Prof Zarnie Lwin OAM shares some advice for junior faculty and trainees beginning their careers in lung cancer research and clinical care. 🎧 Listen to the full episode of Conversations in Lung Cancer Research now. Listen on Apple > buff.ly/due1sdz

100

TOGA @togaanz.bsky.social · 31/08/2026

Interested in developing your expertise in thoracic oncology? TOGA’s 2026 Lung Cancer Preceptorship provides early-career clinicians with the opportunity to learn from experienced clinicians, engage in practical case-based discussions and build connections with others working in the field.

100

TOGA @togaanz.bsky.social · 30/08/2026

Great discoveries start with great ideas. TOGA's Inspirational Research Grant supports research that addresses important questions in thoracic oncology, with the potential to influence future clinical practice and improve outcomes for patients. Grant details: 💰 Amount: $50,000

100

TOGA @togaanz.bsky.social · 29/08/2026

We're pleased to welcome Pfizer as a sponsor of TOGA's 2026 Lung Cancer Preceptorship. Thank you for supporting this important educational initiative and helping create opportunities for the next generation of thoracic oncology clinicians to learn, connect and grow. 📅 Dates: November 20-21

100

TOGA @togaanz.bsky.social · 28/08/2026

🎙️ New episode available A/Prof Mel Moore welcomes Prof Zarnie Lwin OAM for a wide-ranging conversation about her journey in lung cancer research and clinical care. Listen on Apple > buff.ly/due1sdz Spotify > buff.ly/Zde8VHx Show Notes > buff.ly/Qc1N28c

000

TOGA @togaanz.bsky.social · 27/08/2026

🎙️ Out tomorrow: Conversations in Lung Cancer Research In our latest episode, A/Prof Mel Moore sits down with Prof Zarnie Lwin OAM to explore her journey from Burma to training in South Africa and Australia, and a two-year lung cancer fellowship at Princess Margaret Cancer Centre in Toronto.

100

TOGA @togaanz.bsky.social · 27/08/2026

What could the next step be for patients with EGFR exon 20 insertion lung cancer after targeted therapy and chemotherapy? TOGA’s Phase II DEFIANT trial will evaluate datopotamab deruxtecan (Dato-DXd) in patients with EGFR exon 20 insertion NSCLC.

thoraciconcology.org.au

https://thoraciconcology.org.au/news/clinical-trials/defiant-egfr-exon20-insertion-clinical-trial-dato-dxd/

100

TOGA @togaanz.bsky.social · 26/08/2026

Thank you to Pierre Fabre Laboratories for partnering with TOGA as a sponsor of the 2026 Lung Cancer Preceptorship. Together, we're supporting an educational experience that empowers early-career clinicians with the knowledge, confidence and connections to advance lung cancer care.

100

TOGA @togaanz.bsky.social · 25/08/2026

Dr Allison Black highlights the importance of ensuring people across Australia receive the same standard of care, regardless of their smoking history. The panel explores how stigma can affect patients and how healthcare professionals can work towards more respectful, equitable and

100

TOGA @togaanz.bsky.social · 24/08/2026

Looking to enhance your research? Submit your concept and gain access to expert peer review, meaningful consumer feedback, and support to help refine and strengthen your idea. This is your final chance to submit a research concept for 2026. Deadline: 11 September Submit your

100

TOGA @togaanz.bsky.social · 22/08/2026

We're delighted to have Boehringer Ingelheim supporting TOGA's 2026 Lung Cancer Preceptorship. Thank you for supporting the education and development of future leaders in thoracic oncology. We value your partnership and support. 📅 Dates: November 20-21 📍 Location: Sydney

100

TOGA @togaanz.bsky.social · 21/08/2026

Take your lung cancer knowledge to the next level. TOGA’s 2026 Lung Cancer Preceptorship brings together early-career clinicians for two days of expert-led education, interactive case discussions and multidisciplinary learning. 📅 Dates: November 20-21 📍 Location: Sydney

100

TOGA @togaanz.bsky.social · 20/08/2026

In the latest episode of TOGA’s Conversations in Lung Cancer Research, A/Prof Gavin Wright discusses the importance of reducing barriers to screening and addressing the stigma associated with smoking. 🎧 Listen to the full episode now. Listen on Apple > buff.ly/mpWVTTg

100

TOGA @togaanz.bsky.social · 19/08/2026

Advancing research. Supporting innovation. Improving outcomes. The ALK+ NSCLC Inspirational Research Grant is an opportunity for researchers to develop impactful projects that address important questions in ALK-positive lung cancer. Proudly supported by TOGA and ALK Positive Australia, this

110

TOGA @togaanz.bsky.social · 18/08/2026

In the latest episode of TOGA’s Conversations in Lung Cancer Research, A/Prof Henry Marshall joins A/Prof Gavin Wright, Dr Allison Black and Prof Suzanne Chambers to unpack the complex issue of smoking-related stigma in lung cancer. From psychological distress and patient care to participation in

100

TOGA @togaanz.bsky.social · 18/08/2026

Expressions of interest are now open. If you're an early-career clinician with an interest in thoracic oncology, don't miss the opportunity to attend TOGA's 2026 Lung Cancer Preceptorship. 📅 Dates: November 20-21 📍 Location: Sydney Expressions of interest close 4 September 2026.

100

TOGA @togaanz.bsky.social · 17/08/2026

Specialist Lung Cancer Nurses play a vital role in improving care, coordinating treatment and supporting people living with lung cancer. Read our blog "Why Every Service Needs a Specialist Lung Cancer Nurse ">

buff.ly

Why Every Service Needs a Specialist Lung Cancer Nurse - TOGA - Thoracic Oncology Group Australasia

Their work is often invisible, but its impact isn't. Specialist Lung Cancer Nurses are quietly becoming the backbone of modern lung cancer care.

000